- Microbix (MBX) is presenting the utility of its Quality Assessment Products (QAPs) to monitor the end-to-end diagnostic process at the Preanalytical Phase Conference this year hosted by the AACC
- Multiplex monitors molecular assays that detect and distinguish between 4 STIs that cause Genital Ulcer Disease
- Microbix (MBX) is a life sciences innovator, manufacturer, and exporter
- Microbix (MBX) is trading at C$0.48 as of Jul 26, 2022, 12:24 PM ET
Microbix (MBX) is presenting at the Preanalytical Phase Conference this year hosted by the American Association of Clinical Chemistry (AACC).
The company will present the utility of its Quality Assessment Products (QAPs) to monitor the end-to-end diagnostic process. This includes the impact of “preanalytical” sample-handling variables on test accuracy. The company presents the utility of its multi-pathogen “multiplex” and swab-formatted QAPs to monitor molecular assays that detect and distinguish between 4 sexually-transmitted infections (STI) that cause Genital Ulcer Disease (GUD). The conference takes place in Chicago, Illinois, from July 24-28.
Microbix is attending this AACC conference to present important aspects of infectious disease testing, alongside leaders in the global medical diagnostics industry.
The presentation is titled “Novel Herpes Simplex Virus, Varicella Zoster Virus, and Treponema pallidum Quality Control Material for use with Genital Lesion Molecular Detection Assays”.
It outlines the use of Microbix swab positive samples QAPs to validate the whole workflow of molecular assays that detect STIs from the oral and genital types of Herpes Simplex.
Microbix will also be conducting business development activities in relation to its expanding portfolio of QAPs, which includes Health Canada, U.S. FDA, EU “CE mark,” or TGA (Australia) in-vitro-diagnostic regulated SKUs and research-use-only designated SKUs across both liquid-vial and Copan FLOQSwab formats.
These Microbix products and methods can be used to validate processes for new-generation testing practices, such as at-home sample collection, for a wide range of disease screening and diagnostic purposes, including COVID-19 and high-risk HPV infection, among others. The study was conducted in collaboration with FH Health Laboratory of Toronto, Ontario, whose support in sourcing clinical specimens, testing, and tabulation is gratefully acknowledged.
Microbix (MBX) is a life sciences innovator, manufacturer, and exporter of biological products for human health and makes a wide range of critical ingredients and devices for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs) that support clinical lab proficiency testing, enable assay development and validation, or help ensure the quality of clinical diagnostic workflows.
Microbix (MBX) is trading at C$0.48 as of Jul 26, 2022, 12:24 PM ET.
